Further, inhibiting CCR5 through a novel antagonist targeting the CCL5/CCR5 axis suppresses tumor growth and metastasis in TNBC by regulating the CCR5-YAP1 signaling pathway, thereby disrupting pro-tumoral mechanisms (88). Here, CCL5 is linked to neoplasm.